This study identifies the interleukin-2-inducible T cell Kinase (ITK)-mediated phosphorylation of Y218 in the CD28 cytoplasmic domain as key for CAR-T cell function and demonstrates that engineering a synthetic ITK-binding motif into the CAR enhances IL-2 production and antitumor efficacy in vivo.